Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy

Microbiology and Immunology

Volumn 55, Issue 6, 2011, Pages 418-426

  El Shamy, Ahmed ^a,b   Shoji, Ikuo ^a   Saito, Takafumi ^c   Watanabe, Hisayoshi ^c   Ide, Yoshi Hiro ^a   Deng, Lin ^a   Kawata, Sumio ^c   Hotta, Hak ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suez Canal University   (Egypt)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Core; Interferon sensitivity determining region; Interferon ribavirin resistance determining region; Pegylated interferon ribavirin

Indexed keywords

CORE PROTEIN; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERFERON RIBAVIRIN RESISTANCE DETERMINING REGION; INTERFERON SENSITIVITY DETERMINING REGION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN STRUCTURE; VIRUS CORE; VIRUS MUTATION;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 79957623354     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2011.00331.x     Document Type: Article

References (33)

1. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., Lettieri G., Pierri P., Chionne P., Ciccaglione A.R., Sagliocca L. (1998) Correlation between virus genotype and chronicity rate in acute hepatitis C. J Hepatol 28: 939-44.
2. Tanaka E., Kiyosawa K. (2000) Natural history of acute hepatitis C. J Gastroenterol Hepatol 15(Suppl): E97-104.
3. Maekawa S., Enomoto N. (2009) Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 44: 1009-15.
4. Mattsson L., Sonnerborg A., Weiland O. (1993) Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 13: 274-8.
5. Micallef J.M., Kaldor J.M., Dore G.J. (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13: 34-41.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-82.
7. Sarasin-Filipowicz M. (2009) Interferon therapy of hepatitis C: molecular insights into success and failure. Swiss Med Wkly 140: 3-11
8. Backus L.I., Boothroyd D.B., Phillips B.R., Mole L.A. (2007) Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46: 37-47.
9. Enomoto N., Maekawa S. (2010) HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 53: 66-9.
10. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
11. El-Shamy A., Nagano-Fujii M., Sasase N., Imoto S., Kim S.R., Hotta H. (2008) Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 48: 38-47.
12. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Miyakawa Y., Kumada H. (2007) Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50: 361-8.
13. Akuta N., Suzuki F., Sezaki H., Suzuki Y., Hosaka T., Someya T., Kobayashi M., Saitoh S., Watahiki S., Sato J., Matsuda M., Kobayashi M., Arase Y., Ikeda K., Kumada H. (2005) Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-80.
14. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., Kumada H. (2007) Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46: 403-10.
15. El-Shamy A., Kim S.R., Ide Y.H., Sasase N., Imoto S., Deng L., Shoji I., Hotta H. (2011) Polymorphisms of hepatitis C virus non-structural protein 5A and core proteins and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology (in press).
16. Sanjo M., Saito T., Ishii R., Nishise Y., Haga H., Okumoto K., Ito J., Watanabe H., Saito K., Togashi H., Fukuda K., Imai Y., El-Shamy A., Deng L., Shoji I., Hotta H., Kawata S. (2010) Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. J Med Virol 82: 1364-70.
17. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., Mayumi M. (1992) Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 73(Pt 3): 673-9.
18. El-Shamy A., Sasayama M., Nagano-Fujii M., Sasase N., Imoto S., Kim S.R., Hotta H. (2007) Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. Microbiol Immunol 51: 471-82.
19. Ogata S., Nagano-Fujii M., Ku Y., Yoon S., Hotta H. (2002) Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol 40: 3625-30.
20. Fukuhara T., Taketomi A., Okano S., Ikegami T., Soejima Y., Shirabe K., Maehara Y. (2010) Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol 52: 672-680.
21. Sasase N., Kim S.R., Kudo M., Kim K.I., Taniguchi M., Imoto S., Mita K., Hayashi Y., Shoji I., El-Shamy A., Hotta H. (2010) Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b. Intervirology 53: 49-54.
22. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., Mchutchison J.G., Goldstein D.B. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
23. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-4.
24. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-9.
25. Shirakawa H., Matsumoto A., Joshita S., Komatsu M., Tanaka N., Umemura T., Ichijo T., Yoshizawa K., Kiyosawa K., Tanaka E. (2008) Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 48: 1753-60.
26. Okanoue T., Itoh Y., Hashimoto H., Yasui K., Minami M., Takehara T., Tanaka E., Onji M., Toyota J., Chayama K., Yoshioka K., Izumi N., Akuta N., Kumada H. (2009) Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 44: 952-63.
27. Hayashi K., Katano Y., Ishigami M., Itoh A., Hirooka Y., Nakano I., Urano F., Yoshioka K., Toyoda H., Kumada T., Goto H. (2011) Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat 18: 280-86
28. Gale M. Jr., Blakely C.M., Kwieciszewski B., Tan S.L., Dossett M., Tang N.M., Korth M.J., Polyak S.J., Gretch D.R., Katze M.G. (1998) Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 18: 5208-18.
29. Moradpour D., Evans M.J., Gosert R., Yuan Z., Blum H.E., Goff S.P., Lindenbach B.D., Rice C.M. (2004) Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 78: 7400-9.
30. Appel N., Pietschmann T., Bartenschlager R. (2005) Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 79: 3187-94.
31. Yuan H.J., Jain M., Snow K.K., Gale M. Jr., Lee W.M. (2009) Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. J Viral Hepat 17: 208-216.
32. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., Heinrich P.C., Haussinger D. (2003) IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. Faseb J 17: 488-90.
33. De Lucas S., Bartolome J., Carreno V. (2005) Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis 191: 93-99.